Last €9.91 EUR
Change Today -0.086 / -0.86%
Volume 131.0
As of 6:23 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

affymetrix inc (AFF) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/15 - €10.26
52 Week Low
04/14/14 - €4.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AFFYMETRIX INC (AFF)

affymetrix inc (AFF) Related Businessweek News

No Related Businessweek News Found

affymetrix inc (AFF) Details

Affymetrix, Inc. provides life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience. The Affymetrix Core segment is engaged in the development, manufacture, and commercialization of systems for genetic analysis in the life sciences and diagnostic industry. This segment develops and markets GeneChip gene expression products and services; genotyping product line, such as the Axiom product line; arrays and assays with clinical research applications, such as the CytoScan and OncoScan products; QuantiGene line of singleplex and multiplex assays to serve customers in the research and translational medicine markets; and GeneTitan family of products consisting of the GeneTitan instrument system that runs genotyping and gene expression array plates. It also offers life science reagents, such as ExoSAP-IT for a reagent for the clean-up of polymerase chain reaction, and HotStart-IT reagents to inhibit primer dimer formation; enzymes; purification kits; and biochemicals for life science researchers. The eBioscience segment is involved in the development, manufacturing, marketing, and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging, and other protein-based analyses. This segment offers a portfolio of antibodies and reagents, as well as a range of the QuantiGene and Procarta assay portfolio. The company sells its products directly and through third party distributors to genomic research centers, academic institutions, government, and private laboratories, as well as pharmaceutical, diagnostic, and biotechnology companies. Affymetrix, Inc. was founded in 1991 and is headquartered in Santa Clara, California.

1,100 Employees
Last Reported Date: 03/3/14
Founded in 1991

affymetrix inc (AFF) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $498.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $281.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $376.5K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $331.3K
Compensation as of Fiscal Year 2013.

affymetrix inc (AFF) Key Developments

Affymetrix, Inc. Appoints Merilee Raines as Member of the Board of Directors and Audit Committee

Affymetrix, Inc. has appointed Merilee Raines as a new member of the board of directors. Ms Raines will serve as a member of the Audit Committee. Ms Raines served as CFO of IDEXX Laboratories (IDXX), Inc. from 2003 until her retirement in 2013. Prior to becoming CFO, she held management positions with IDEXX Laboratories, including vice president of Finance, Treasurer, Director of Finance, and Controller. Ms Raines is also a member of the Board of Directors of Watts Water Technologies (WTS) and Aratana Therapeutics (PETX).

Affymetrix Announces Preliminary Unaudited Sales Results for the Fourth Quarter of 2014; Appoints Merilee Raines to board's audit committee

Affymetrix announced preliminary unaudited sales results for the fourth quarter of 2014. For the quarter, the company reported revenues of $93 million, up 2.2% year on year. The company also announced that Merilee Raines has been appointed the board's audit committee effective January 12, 2015. Raines served as CFO of IDEXX Laboratories (IDXX) from 2003 until her retirement in 2013.

Affymetrix Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2014 and for the Year 2015

Affymetrix Inc. provided unaudited earnings guidance for the fourth quarter and full year 2014 and for the year 2015. The company expects total revenue for the fourth quarter of 2014 to be approximately $93 million. For fiscal 2014, the Company expects total revenue of approximately $348 million, representing a 9% growth over the prior year, after adjusting for the sale of its Anatrace business with revenues of $4.5 million and a one-time license payment of $5.3 million in 2013. For the year 2014, the company expects revenues of $348 million, which was the 9% growth over the prior year. For the year 2015, the company expects gross margins will be consistent with what the company saw in 2014, just a little bit above 60%, with adjusted EBITDA in the 16% to 18% range.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFF:GR €9.91 EUR -0.086

AFF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $39.78 USD +2.07
Luminex Corp $17.90 USD +0.15
Pacific Biosciences of California Inc $8.17 USD +0.18
Sequenom Inc $3.68 USD +0.09
Takara Bio Inc ¥1,352 JPY -3.00
View Industry Companies

Industry Analysis


Industry Average

Valuation AFF Industry Range
Price/Earnings 100.0x
Price/Sales 2.3x
Price/Book 3.0x
Price/Cash Flow 2,160.0x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMETRIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at